News for Pharnext SA (ALPHA.PA)

Published at

Mar 11, 2024 4:35 PM

by marketscreener.com

neutral

neutral

Pharnext Sca : Pharnext takes full stock of its operating, strategic and financial situation -March 11, 2024 at 11:35 am EDT

PARIS, France, March 11, 2024, 04:30 pm CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

PNEXF ALPHA.PA

Read more →
Published at

Mar 2, 2024 7:06 PM

by gurufocus.com

positive

positive

Pharnext PLEO-CMT-FU Phase 3 Open Label Extension Study Call Transcript

Jan 06, 2020 / 09:30PM GMTOperator Welcome to the Pharnext conference call. This call is being webcast live on Pharnext website at pharnext.com. Please be advis

PNEXF ALPHA.PA

Read more →
Published at

Feb 28, 2024 8:35 AM

by marketscreener.com

positive

positive

Pharnext Sca : Pharnext progresses in analyzing data from pivotal Phase III study of PXT3003 in Charcot-Marie-Tooth disease type 1A -February 28, 2024 at 02:35 am EST

PARIS, France, February 28, 2024, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

PNEXF ALPHA.PA

Read more →
Published at

Jan 17, 2024 8:35 AM

by marketscreener.com

positive

positive

Pharnext Sca : Pharnext commits to a drastic cost-cutting plan and receives support from its financial partners to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type

PARIS, France, January 17, 2024, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

PNEXF ALPHA.PA

Read more →
Published at

Jan 17, 2024 8:35 AM

by marketscreener.com

positive

positive

Pharnext Sca : Pharnext commits to a drastic cost-cutting plan to further enhance the value of its drug candidate for Charcot-Marie-Tooth disease type 1A -January 17, 2024 at 02:35 am EST

PARIS, France, January 17, 2024, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

PNEXF ALPHA.PA

Read more →
Published at

Nov 27, 2023 8:35 AM

by marketscreener.com

positive

positive

Pharnext Sa : Pharnext unveils new calendar for negotiations valuing its drug candidate in Charcot-Marie-Tooth disease type 1A -November 27, 2023 at 02:35 am EST

PARIS, France, November 27, 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

PNEXF ALPHA.PA

Read more →
Published at

Nov 20, 2023 8:35 AM

by marketscreener.com

positive

positive

Pharnext Sa : Pharnext announces successful manufacturing of registration batches of PXT3003 in the United States -November 20, 2023 at 02:35 am EST

PARIS, France, November 20, 2023, 08:30 am CET – Pharnext SCA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

PNEXF ALPHA.PA

Read more →
Published at

Sep 28, 2023 8:35 AM

by marketscreener.com

positive

positive

Pharnext Sa : Pharnext updates on the development program in China for PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A) -September 28, 2023 at 02:35 am EDT

PARIS, France, 28 September 2023, 08:30 am CET – Pharnext SA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high...

PNEXF ALPHA.PA

Read more →
Published at

Sep 26, 2023 10:35 AM

by marketscreener.com

positive

positive

Pharnext Sa : Edison Investment Research maintains its valuation following the Company's latest announcements -September 26, 2023 at 04:35 am EDT

PARIS, France, September 26, 2023 at 08:30 am CET – Pharnext SCA , an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with...

PNEXF ALPHA.PA

Read more →
Published at

Sep 18, 2023 7:00 PM

by globenewswire.com

mixed

mixed

Charcot-Marie-Tooth Disease Market Size and Share to Grow by 2032, Predicts DelveInsight | Key Players in the Market - Pharnext, MedDay, HELIXMITH, ENCell, InFlectis, Addex, Augustine, DTx Pharma

The increase in the Charcot-Marie-Tooth disease market size is a direct consequence of increasing prevalent population of Charcot-Marie-Tooth disease...

VCNX SEEL PNEXF ORYZF ORYN.MX ORY.MC MDTN.MX MDT.BA MDT LLY.MX LLY.DE LLY.BA LLY LILY34.SA IONS.MX IONS HLUYY HLUKF BSX.MX BSX-PA BSX BIVI B1SX34.SA ANVS ALPHA.PA ALEC ABTCL.SN ABT.SN ABT 2M6.DE 0Y6X.L 0RDB.L 0Q1G.L 0JDI.L 0HOY.L PRTA DNLI 4356.T 0Y3M.L

Read more →